Companies › Beijing Youcare Kechuang Pharmaceutical Technology
3 active drug programs in 3 registered trials: 3 Phase 1; Cardiovascular, Oncology, Infectious disease; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| YKYY033 Injection | – | Phase 1 | Venous Thromboembolism (VTE) | Nov 2027 |
| YKYY031 for injection | – | Phase 1 | Malignant Neoplasms | Dec 2027 |
| YKYY025 | – | Phase 1 | Respiratory Syncytial Virus (RSV) | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07786779 | YKYY033 Injection | Phase 1 | Venous Thromboembolism (VTE) | Cardiovascular | Nov 2027 |
| NCT07631793 | YKYY031 for injection | Phase 1 | Malignant Neoplasms | Oncology | Dec 2027 |
| NCT07694557 | YKYY025 | Phase 1 | Respiratory Syncytial Virus (RSV) | Infectious disease | Jul 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.